Kirin Cashes Out of Amgen Drug Joint Venture for $780M Post author:Sam Post published:October 30, 2017 Post category:BioPharma Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen. Source: BioSpace You Might Also Like Genentech Exec Jumps Ship to Become CMO at Gritstone Oncology May 2, 2017 BioTime Subsidiary AgeX Therapeutics, Inc. Appoints Ph.D. As VP Of New Technology Discovery July 12, 2017 Bone Biologics Announces Appointment Of To Company???s Board Of Directors August 3, 2017
BioTime Subsidiary AgeX Therapeutics, Inc. Appoints Ph.D. As VP Of New Technology Discovery July 12, 2017
